The UK and US have agreed to a significant commercial pact that will ensure zero import taxes on UK drug shipments entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to raise expenditure on medicines through the NHS. This pledge guarantees that import taxes on these crucial exports will remain at zero for a duration of three years.
This development comes after recent warnings to hike import taxes on branded pharmaceutical products, with potential rates mentioned as high as double the cost.
"This deal between the Britain bolsters the international landscape for new treatments and brings much-needed equity to transatlantic drug exports," a release declared.
Commercial Impact
Drugs represent one of the the United Kingdom's largest export categories to the US, which is by far the primary destination for major UK drugmakers.
Trade data reveal that in the one-year period prior to last September, the UK sold drugs valued at over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement safeguards jobs, increases funding and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The agreement involves several key pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall public funding on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Previously, rebates topped 20%.
Industry Background
The deal comes amid a ongoing row between the drug companies and the ministers over drug pricing and regulatory access.
This friction were heightened by arguments that American consumers were paying several times more for the same drugs than patients in the other developed nations.
In recent months, several large manufacturing plans in the UK have been paused or abandoned, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
